Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study

Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study

Recombinant human TPO (rhTPO) is effective for refractory/relapsed primary immune thrombocytopenia (ITP), but optimal dosing regimen remains elusive. In this multicenter, randomized, controlled trial, a total of 282 adult ITP patients (mean age 47.3 years; 82 men) with a platelet count ≤30 × 109/L o...

Full description

Bibliographic Details
Main Authors: Xiaofan Liu, Yusheng Bai, Tao Wang, Yanping Song, Feng Sun, Ruixiang Xia, Feiyue Zhu, Jun Ma, Quanyi Lu, Xu Ye, Xinrong Zhan, Linjie Li, Xinhong Guo, Shuqin Cheng, Yan Li, Zhiqiang Guo, Youhua Chen, Shenxian Qian, Ling Qin, Qing Zhang, Sunqiong Cao, Renchi Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Platelets
Subjects:
dosing regimen
efficacy
immune thrombocytopenia
pharmacokinetics
recombinant human thrombopoietin
Online Access:http://dx.doi.org/10.1080/09537104.2022.2157806

Internet

http://dx.doi.org/10.1080/09537104.2022.2157806

Similar Items